MA-BRIGHTCOVE
1.2.2021 15:02:08 CET | Business Wire | Press release
Brightcove Inc. (NASDAQ: BCOV), the global leader in video for business, and South by Southwest® (SXSW® ) Conference and Festivals announced today that Brightcove has been chosen as the official video partner for the all-digital SXSW Online and SXSW EDU Online events, which, for the first time, will be completely virtual and streamed to attendees around the globe on March 16–20, 2021.
Streaming an event at the scale of SXSW required the organization to ensure that its video technology platform was not only reliable but could deliver a broadcast-grade viewing experience with a high level of security. With Brightcove, SXSW will join an expanding roster of innovative, global organizations that have successfully streamed content to massive audiences on their viewing device of choice.
SXSW Online will bring together creative thinkers from all facets of the entertainment, media, and technology industries to experience a diverse combination of pre-recorded and live programming, providing up to 650 hours of content to attendees. Through Brightcove’s award-winning, highly-scalable, and flexible digital video platform, SXSW Online will span five different channels, emulating iconic SXSW stages from years past, and give attendees the unique ability to switch channels for different content in real-time, one major benefit of at-home streaming.
“This has been such a time of change and we, like the entire world, are reshaping our perspective on how we connect. Given the obstacles faced in 2020 and beyond, there has never been a more critical time to come together to address some of the most important societal issues and challenges that lie ahead,” said Roland Swenson, CEO and Co-Founder of SXSW. “We’re excited to work with Brightcove to bring everyone a seamless digital experience at SXSW Online this March. As a leader in the video industry, Brightcove will help us meet our goals while expanding the reach and capacity of SXSW’s programming.”
SXSW will use Brightcove Beacon® to enable attendees to consume content online via web browser or via Apple TV, Roku, Fire TV, Android TV, and Samsung TV. Brightcove’s over-the-top (OTT) capabilities provide a consistent, high-quality video streaming experience regardless of device or channel. Additionally, by using Brightcove’s distinct video capabilities, SXSW and festival partners can expect an unparalleled experience through:
- Utilization of Backend Analytics: SXSW will use Brightcove’s real-time data and analytics to track attendees’ content consumption to determine what they are watching and for how long in order to gain valuable insights that will help inform and optimize future programming.
- Content Security: SXSW will use Brightcove’s secure custom authentication to grant attendees access to all relevant content.
- Signature Brand Control: SXSW will use custom branding for all live and on-demand content, enabling a consistent brand experience across each event.
- Cloud Playout Technology: SXSW is the first Brightcove client to utilize Brightcove’s new full-featured Cloud Playout for a streamlined workflow, which enables content owners and organizations to quickly and seamlessly program a scheduled playout of both on-demand and live footage.
“Brightcove is honored to work with SXSW to harness the power of video and bring the SXSW community together virtually. We know firsthand that, despite the challenges of transitioning an iconic event from in-person to 100% virtual, the right technology leads to success for our customers and the audiences they serve,” said Jeff Ray, Brightcove’s CEO. “Brightcove’s technology is the most reliable, scalable, secure, and broadcast-grade, providing all SXSW attendees with an unparalleled viewing experience that’s rooted in quality and innovation.”
As part of the partnership, Brightcove will also be the sole sponsor of the Brightcove Illumination Award, a new initiative to honor a filmmaker on the rise and to celebrate the innovation and creativity of new artists. Further details on nominees and jurists will be released closer to the festival.
All conference keynotes, featured speakers, film festival screenings, and music festival showcases will be available for streaming on the SXSW Online Platform.
About SXSW Film Festival
Now in its 28th year, SXSW Film Festival brings together creatives of all stripes over nine days to experience a diverse lineup and access to thousands of SXSW Conference sessions with visionaries from all corners of the entertainment, media, and technology industries.
About SXSW
SXSW dedicates itself to helping creative people achieve their goals. Founded in 1987 in Austin, Texas, SXSW is best known for its conference and festivals that celebrate the convergence of the interactive, film, and music industries. In 2021, the event moves to a digital format. SXSW Online offers conference sessions, music showcases, film screenings, exhibitions, and a variety of networking and professional development opportunities. An essential destination for global professionals, SXSW Online 2021 will take place March 16 - March 20. For more information, please visit sxsw.com . To register for the event, please visit sxsw.com/attend .
About Brightcove
When video is done right, it can have a powerful and lasting effect. Hearts open. Minds change. Creativity thrives. Since 2004, Brightcove has been helping customers discover and experience the incredible power of video through its award-winning technology, empowering organizations in more than 70 countries across the globe to touch audiences in bold and innovative ways.
Brightcove achieves this by developing technologies once thought impossible, providing customer support without parallel or excuses, and leveraging the expertise and resources of a global infrastructure. Video is the world’s most compelling, exciting medium. Visit www.brightcove.com for more information. Video That Means Business.™
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005516/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom